Acetadote is owned by Cumberland Pharms.
Acetadote contains Acetylcysteine.
Acetadote has a total of 5 drug patents out of which 0 drug patents have expired.
Acetadote was authorised for market use on 23 January, 2004.
Acetadote is available in injectable;intravenous dosage forms.
Acetadote can be used as method of treating acetaminophen overdose with acetylcysteine solutions, composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy.
The generics of Acetadote are possible to be released after 06 April, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399445 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
US8653061 | CUMBERLAND PHARMS | Acetylcysteine composition and uses thereof |
Aug, 2025
(2 years from now) | |
US8148356 | CUMBERLAND PHARMS | Acetylcysteine composition and uses therefor |
May, 2026
(3 years from now) | |
US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(8 years from now) | |
US8722738 | CUMBERLAND PHARMS | Acetycysteine compositions and methods of use thereof |
Apr, 2032
(9 years from now) |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic